Etop Ibcsg Partners Foundation

This study tested whether adding an immunotherapy drug (atezolizumab) to standard treatment helps people with advanced malignant pleural mesothelioma, a rare lung cancer. About 400 adults with this cancer received either the standard treatment or the standard treatment plus atezo…

This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well these treatments slow tumor growth b…

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…

This study tested a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus chemotherapy in 95 people with advanced EGFR-mutant lung cancer whose tumors had stopped responding to standard targeted therapy. The goal was to see if this new mix could control the c…

This study tested whether a combination of triptorelin and exemestane works better than triptorelin and tamoxifen in premenopausal women with hormone-sensitive breast cancer. Over 2,600 women who had surgery to remove their cancer took part. The goal was to see which treatment he…

This study tested whether adding ovarian suppression (stopping the ovaries from making estrogen) and switching to a different hormone drug (exemestane) could better prevent breast cancer from returning in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women …